Member Info for D-Geeman

Watching2;

He’s been here for years constantly churning out positivity

Trying to spread confidence about a company who (sic) (which) he and others have lost a lot of money in

He’s a Very sad person

Ceesor, you don't include Boris with Liz and K?!

I have an American friend. I remember her comment that "Hilary told so many lies" people wouldn't vote for her in the general election. Friend was right.

Friend is very pro-Trump and doesn't mind his lies now. It's weird.

(And I used to vote Tory.)

'short sharp shock'

I think it will be a 'long sharp shock' but let's see.. Nothing I can do about it anyway.

Just out of interest and now it's evening, is there anyone here who thinks Trump is doing the right thing for the USA? Maybe we just don't get it and he's good for north America?

I'm just trying to remain open minded despite the way it looks...

'Clearly the drop is across the board'; I hope CC isn't thinking like that, with the CLN so close. The drop created by Trump will have a material impact on dilution here.

Perhaps the sp today will galvanise some action by the management. Every cloud / silver lining and all that..

(They might even go through old emails looking for suggestions and license AVA6k to a veterinary chemo company; rabbits – and cats and dogs – and hats and all that..)

I wonder if they can they do a 50 / 50, half cash / half shares, for the CLN for a month..

(And for those who don't appreciate McMuff' and Wyn's reality posts, is this a bit more to your taste?

yeboha

Posts: 844

Price: 35.75

No Opinion

RE: Now’s the time31 Mar 2025 16:16

100% this will be back over 40 tomorrow')

'why do you bother'

you do well to keep going Wyn.

How's the new car?

Maybe people are actually keeping quiet at the moment.

Why risk getting caught for an obvious leak now (M & A people put out slightly different figures to see which one emerges in the media) when could've made money from less obvious leak earlier.

'If Sidara walked away because of the Macros last time' .. then they must be seriously interested to have come back.

That's short positions showing now.

Total 5.01% (was? 4.51? yesterday I think)

Partly down to Cubist Systematic Strategies, LLC 0.50% +0.01% 2 Apr 2025

Maybe they were on 0.49% yesterday so increase is only 0.1% but means that the whole 0.5% comes up with short tracker today.

" only about 15% of clinical trials end on time, and more than 50% of delays are related to recruitment problems." Yes JFK, explains a lot.

I wondered whether docs felt awkward mentioning trials - for a variety of possible reasons - which prompted my search but that doesn’t seem to be the case.

Https://subjectwell.com/doctors-patients-clinical-trials/

Why Aren’t Doctors Telling Their Patients About Clinical Trials?

2018 research but maybe not much has changed.

'71% of people worldwide who have not participated in a clinical trial would be willing to. Yet only 25% of people managing a disease have had their doctor or nurse recommend a clinical trial'

Cont..

for the treatment of non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Other active clinical sites in the study include Brigham and Women’s Hospital (BWH) and MS Center at Yale Medical Center.

The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) characterized by progressive neurological decline without relapses.

Dr. Pavan Bhargava, MD, Associate Professor of Neurology and principal investigator at JHU, emphasized the importance of advancing novel treatments for na-SPMS: “Patients with non-active SPMS currently have limited treatment options, and there is an urgent need for therapies that can modulate compartmentalized neuroinflammation and potentially slow disease progression. We are excited to participate in this clinical trial and explore the potential benefits of foralumab in this underserved population.”

“The addition of Johns Hopkins University to our Phase 2 trial to is a significant milestone in our mission to develop a novel approaches and treatment for na-SPMS.” Commented William A. Clementi, PharmD, Chief Development Officer of Tiziana Life Sciences. “Intranasal foralumab has demonstrated promising potential in modulating the immune system to reduce neuroinflammation, and we are eager to continue advancing this study to provide new hope for patients facing this disabling condition.”

'Trolls are working hard today 🤣'

And the SP is up +8.28% which rather suggests that 'trolls' have zero influence.

Press Releases

SEC Filings

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced dosing has commenced at Johns Hopkins University (JHU) Autoimmunity Center of Excellence, the third clinical site in its Phase 2 trial evaluating intranasal foralumab for the treatment of

GlobeNewswire

•

26 minutes ago

Presumably they have a team off accountants working day-in, day-out, so how difficult to audit the accounts? And only one division requires the fine tooth comb. We're expecting suspension after the RNS but surely it would be relatively brief rather than months and months that some are suggesting.

I should've scrolled down ;-)

'my *wife* really fancies a new kitchen'

I reckon she'd correct him to "OUR kitchen" :-)